In a report published Friday, Morgan Stanley analyst Steve Beuchaw reiterated an Equal-Weight rating on Veracyte Inc. VCYT, but lowered the price target from $10.00 to $9.00.
In the report, Morgan Stanley noted, "Despite lower guidance and a higher share count, shares remain inexpensive relative to growth. Organic growth of 40% in '16Eis among the fastest in the group and supports a 2.6x '16E multiple; updated PT $9 from $10."
Veracyte closed on Thursday at $8.30.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in